These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31841591)

  • 1. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
    Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
    Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
    Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
    Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
    Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
    Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
    BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
    Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
    Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
    Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T
    Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
    Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
    Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
    Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
    Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
    Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
    Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
    Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
    Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
    Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
    Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
    Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
    Nakabayashi H; Shimizu K
    Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.